Cargando…
Antibody-based therapies for emerging infectious diseases.
In the 19th century, it was discovered that immune sera were useful in treating infectious diseases. Serum therapy was largely abandoned in the 1940s because of the toxicity associated with the administration of heterologous sera and the introduction of effective antimicrobial chemotherapy. Recent a...
Autor principal: | Casadevall, A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
1996
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2626792/ https://www.ncbi.nlm.nih.gov/pubmed/8903230 |
Ejemplares similares
-
The Ebola Epidemic Crystallizes the Potential of Passive Antibody Therapy for Infectious Diseases
por: Casadevall, Arturo, et al.
Publicado: (2015) -
The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19
por: Casadevall, Arturo, et al.
Publicado: (2021) -
Monoclonal antibody-based therapies for microbial diseases
por: Saylor, Carolyn, et al.
Publicado: (2009) -
Emerging antibody-based products for infectious diseases: Planning for metric ton manufacturing
por: Whaley, Kevin J, et al.
Publicado: (2021) -
The Damage-Response Framework of Microbial Pathogenesis and Infectious Diseases
por: Pirofski, Liise-anne, et al.
Publicado: (2008)